Alnylam Pharma (NASDAQ:ALNY) target bumped down to $77.00, released a ratings update earlier today by Chardan Capital
- Updated: October 5, 2016
Yesterday Alnylam Pharma (NASDAQ:ALNY) traded 2.52% higher at $70.30. The company’s 50-day moving average is $72.86 and its 200-day moving average is $66.46. The last stock close price is up 5.78% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was up over the average, with 1,965,395 shares of ALNY changing hands over the typical 643,269
Chardan Capital reduced the stock price target of Alnylam Pharma (NASDAQ:ALNY) to $77.00 reporting a possible upside of 0.10%.
On 09/29/2016, Janney Capital released a statement about Alnylam Pharma (NASDAQ:ALNY) upped the target price from $0.00 to $74.00. At the time, this suggested a downside of -0.03%.
Recent Performance Chart
Alnylam Pharma has 52 week low of $49.96 and a 52 week high of $110.75 and has a market capitalization of $0.
A total of 11 brokerages have issued a ratings update on Alnylam Pharma. Three brokerages rating the company a strong buy, 8 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $117.09.
Brief Synopsis On Alnylam Pharma (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.